Compare AMTB & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMTB | TYRA |
|---|---|---|
| Founded | 1979 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2018 | 2021 |
| Metric | AMTB | TYRA |
|---|---|---|
| Price | $29.19 | $21.05 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 15 |
| Target Price | $31.88 | ★ $47.45 |
| AVG Volume (30 Days) | 282.6K | ★ 1.2M |
| Earning Date | 10-22-2026 | 11-04-2026 |
| Dividend Yield | ★ 1.26% | N/A |
| EPS Growth | ★ 386.36 | N/A |
| EPS | ★ 0.97 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.20 | N/A |
| P/E Ratio | $30.06 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.62 | $12.98 |
| 52 Week High | $30.60 | $40.65 |
| Indicator | AMTB | TYRA |
|---|---|---|
| Relative Strength Index (RSI) | 47.22 | 41.02 |
| Support Level | $28.31 | $18.66 |
| Resistance Level | $30.19 | $27.00 |
| Average True Range (ATR) | 0.78 | 1.44 |
| MACD | -0.11 | -0.15 |
| Stochastic Oscillator | 25.67 | 19.80 |
Amerant Bancorp Inc is a bank holding company. Through its bank, it provides individuals and businesses deposit, credit, investment, wealth management, and fiduciary services, both in the United States and to select international customers. The bank also provides banking services through traditional channels, such as banking centers and ATMs, as well as via secure websites, mobile devices and telephones.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.